Denali Therapeutics Inc. Share Price
NASDAQ: DNLI | Mid CapDenali Therapeutics Inc. Stock Performance
Open $24.32 | Prev. Close $24.36 | Circuit Range N/A |
Day Range $24.01 - $24.48 | Year Range $12.61 - $27.27 | Volume 64,146 |
Average Traded $24.22 |
Denali Therapeutics Inc. Share Price Today
As of 19 August 2026, Denali Therapeutics Inc.'s share price is $24.31. The stock opened at $24.32, compared to its previous close of $24.36. During today's trading session, Denali Therapeutics Inc.'s share price traded between $24.01 and $24.48, with an average price of $24.24. Over the past 52 weeks, the stock has recorded a high of $27.27 and a low of $12.61. In terms of performance, Denali Therapeutics Inc.'s share price has risen by 14.75% over the last six months and is up 58.99% on a year-on-year basis.
Denali Therapeutics Inc. Share Price Chart
Denali Therapeutics Inc. Stock Fundamentals & Key Indicators
Market Cap $4.20B | PE Ratio (TTM) -8.19 | Dividend Yield N/A |
EPS (TTM) $-2.97 | Revenue (TTM) N/A | Return On Equity (TTM) -50.56% |
Profit Margin N/A | Debt to Equity 0.10 | Quarterly Earnings Growth YoY N/A |
Denali Therapeutics Inc. Quarterly Profit & Loss
All figures in USD
Denali Therapeutics Inc. Annual Profit & Loss
All figures in USD
About Denali Therapeutics Inc.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; DNL343 eIF2B activator program for amyotrophic lateral sclerosis; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Denali Therapeutics Inc. Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $22.80 | $24.36 | +5.85% |
Jul 2026 | $25.83 | $23.01 | -10.54% |
Jun 2026 | $20.86 | $25.72 | +22.30% |
May 2026 | $18.53 | $21.03 | +12.46% |
Apr 2026 | $19.57 | $18.70 | -2.50% |
Mar 2026 | $21.07 | $19.18 | -9.46% |
Feb 2026 | $21.27 | $21.18 | -2.69% |
Jan 2026 | $16.57 | $21.77 | +31.86% |
Dec 2025 | $19.13 | $16.51 | -15.20% |
Nov 2025 | $16.12 | $19.47 | +19.59% |
Oct 2025 | $15.03 | $16.28 | +12.08% |
Sep 2025 | $15.10 | $14.53 | -5.00% |
DNLI Share Price FAQs
What is Denali Therapeutics Inc. share price today?
What is the 52 week high and 52 week low of Denali Therapeutics Inc. stock?
What is DNLI's market capitalisation today?
What is DNLI's net income for the last quarter?
What is the 5 year returns of DNLI?
What is the high & low stock price of DNLI today?
Can I buy DNLI shares in India?